Investigating New Radiation Therapy for Hard-to-Treat Lung Cancer Patients
NCT05624996 · RecruitingThis clinical trial looks at the effects of adding a special type of radiation therapy called stereotactic body radiation therapy (SBRT) to the usual treatment for non-small cell lung cancer that cannot be treated with surgery. The usual treatment includes other types of radiation therapy, chemotherapy, and sometimes immunotherapy. The goal is to see if this new approach can help patients live longer and improve their quality of life.
Locations and contact
This trial is running at 471 locations. The first 8 are listed here.
- University of Alabama at Birmingham Cancer CenterBirmingham, AlabamaRecruiting
- The Kirklin Clinic at Acton RoadBirmingham, AlabamaRecruiting
- Gulf Health Hospitals Inc/Infirmary Cancer Care - MalbisDaphne, AlabamaRecruiting
- Thomas HospitalFairhope, AlabamaRecruiting
- Mobile Infirmary Medical CenterMobile, AlabamaRecruiting
- Gulf Health Hospitals Inc/Infirmary Cancer Care - SaralandSaraland, AlabamaRecruiting
- Kingman Regional Medical CenterKingman, ArizonaRecruiting
- Cancer Center at Saint Joseph'sPhoenix, ArizonaRecruiting
Who can join
Adults aged 18 and older can join the study. Both men and women with a type of lung cancer that cannot be operated on are welcome. Participants must have a confirmed diagnosis and certain health conditions that allow them to receive treatment. The trial team will check to see if you meet the requirements before you can join.
What happens during the trial
Participants will be randomly assigned to one of two groups. One group will receive standard treatment with regular radiation and chemotherapy. The other group will receive the new treatment that includes SBRT along with the same chemotherapy. Everyone will then receive additional treatment with either immunotherapy or another medication based on their needs.
The trial team
The trial is sponsored by NRG Oncology, with Dr. Charles B Simone as the principal investigator.
Important dates
The trial started on July 12, 2023, and is expected to finish on October 15, 2031. The team is currently enrolling new participants.
Additional information
This is a Phase 3 trial, meaning it is looking at how well the treatment works and how safe it is. The trial is regulated by the FDA and aims to include about 474 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →